	US 11,746,144 B2
	Compositions and methods for treating a COVID-19 infection
Ivet Bahar, Wexford, PA (US); Hongying Cheng, Pittsburgh, PA (US); She Zhang, Pittsburgh, PA (US); Rebecca Porritt, Sherman Oaks, CA (US); and Moshe Arditi, Encino, CA (US)
Assigned to University of Pittsburgh—Of The Commonwealth System of Higher Education, Pittsburgh, PA (US); and Cedars-Sinai Medical Center, Los Angeles, CA (US)
Filed by UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, Pittsburgh, PA (US); and CEDARS-SINAI MEDICAL CENTER, Los Angeles, CA (US)
Filed on Jul. 14, 2021, as Appl. No. 17/375,601.
Claims priority of provisional application 63/051,481, filed on Jul. 14, 2020.
Prior Publication US 2022/0235119 A1, Jul. 28, 2022
Int. Cl. C07K 16/12 (2006.01); A61K 39/215 (2006.01); A61P 31/14 (2006.01)

CPC C07K 16/1271 (2013.01) [A61K 39/215 (2013.01); A61P 31/14 (2018.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01)]

23 Claims

1. A method of treating a COVID-19 infection in a subject, comprising administering to the subject an effective amount of one or more of a humanized mAb 6D3, a humanized mAb 14G8, and a functional fragment thereof.